Overview

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

Status:
Completed
Trial end date:
2019-02-22
Target enrollment:
Participant gender:
Summary
This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video. The total planned number of subjects is approximately 10, with each subject receiving OPN-375 186 μg twice a day.
Phase:
Phase 3
Details
Lead Sponsor:
Optinose US Inc.
Treatments:
Fluticasone
Xhance